Clinical Trial Update: Galantamine for Cognitive Deficits in Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

Update on a Phase 2/Phase 3 clinical trial evaluating galantamine for cognitive deficits in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Galantamine (galantamine)

Snippet

Sponsor: Yale University | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED